CN1329055A - 一种新的多肽——人内收蛋白beta亚基10和编码这种多肽的多核苷酸 - Google Patents

一种新的多肽——人内收蛋白beta亚基10和编码这种多肽的多核苷酸 Download PDF

Info

Publication number: CN1329055A
Authority: CN; China
Prior art keywords: polypeptide; polynucleotide; adducin; beta subunit; people
Prior art date: 2000-06-19
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

CN 00116591

Other languages

English (en)

Chinese (zh)

Inventor

毛裕民

谢毅

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Shanghai Biowindow Gene Development Inc

Original Assignee

Shanghai Biowindow Gene Development Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-06-19

Filing date

2000-06-19

Publication date

2002-01-02

2000-06-19 Application filed by Shanghai Biowindow Gene Development Inc filed Critical Shanghai Biowindow Gene Development Inc

2000-06-19 Priority to CN 00116591 priority Critical patent/CN1329055A/zh

2001-06-18 Priority to AU93624/01A priority patent/AU9362401A/en

2001-06-18 Priority to PCT/CN2001/000989 priority patent/WO2002002617A1/fr

2002-01-02 Publication of CN1329055A publication Critical patent/CN1329055A/zh

Status Pending legal-status Critical Current

Links

102000011759 adducin Human genes 0.000 title claims abstract description 147
108010076723 adducin Proteins 0.000 title claims abstract description 147
108091033319 polynucleotide Proteins 0.000 title claims abstract description 111
239000002157 polynucleotide Substances 0.000 title claims abstract description 111
102000040430 polynucleotide Human genes 0.000 title claims abstract description 111
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 116
229920001184 polypeptide Polymers 0.000 claims abstract description 109
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 108
238000000034 method Methods 0.000 claims abstract description 80
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 35
201000010099 disease Diseases 0.000 claims abstract description 29
239000005557 antagonist Substances 0.000 claims abstract description 18
230000000694 effects Effects 0.000 claims abstract description 10
201000011510 cancer Diseases 0.000 claims abstract description 9
208000026278 immune system disease Diseases 0.000 claims abstract description 4
208000031886 HIV Infections Diseases 0.000 claims abstract description 3
208000037357 HIV infectious disease Diseases 0.000 claims abstract description 3
206010061218 Inflammation Diseases 0.000 claims abstract description 3
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims abstract description 3
230000004054 inflammatory process Effects 0.000 claims abstract description 3
239000000523 sample Substances 0.000 claims description 64
108090000623 proteins and genes Proteins 0.000 claims description 59
238000009396 hybridization Methods 0.000 claims description 35
239000002773 nucleotide Substances 0.000 claims description 31
125000003729 nucleotide group Chemical group 0.000 claims description 31
239000012634 fragment Substances 0.000 claims description 29
230000014509 gene expression Effects 0.000 claims description 27
150000007523 nucleic acids Chemical class 0.000 claims description 24
150000001875 compounds Chemical class 0.000 claims description 21
102000039446 nucleic acids Human genes 0.000 claims description 18
108020004707 nucleic acids Proteins 0.000 claims description 18
230000000295 complement effect Effects 0.000 claims description 15
239000013604 expression vector Substances 0.000 claims description 13
239000013598 vector Substances 0.000 claims description 12
239000013612 plasmid Substances 0.000 claims description 11
239000000556 agonist Substances 0.000 claims description 10
238000006243 chemical reaction Methods 0.000 claims description 10
239000003814 drug Substances 0.000 claims description 9
238000002360 preparation method Methods 0.000 claims description 8
239000003112 inhibitor Substances 0.000 claims description 7
241000700605 Viruses Species 0.000 claims description 6
230000003321 amplification Effects 0.000 claims description 6
238000003199 nucleic acid amplification method Methods 0.000 claims description 6
230000000692 anti-sense effect Effects 0.000 claims description 5
238000003745 diagnosis Methods 0.000 claims description 4
238000001727 in vivo Methods 0.000 claims description 4
239000003937 drug carrier Substances 0.000 claims description 3
238000002493 microarray Methods 0.000 claims description 3
239000008194 pharmaceutical composition Substances 0.000 claims description 3
230000008485 antagonism Effects 0.000 claims description 2
238000013459 approach Methods 0.000 claims description 2
208000022602 disease susceptibility Diseases 0.000 claims description 2
238000004088 simulation Methods 0.000 claims description 2
239000003981 vehicle Substances 0.000 claims description 2
125000003275 alpha amino acid group Chemical group 0.000 claims 6
238000004519 manufacturing process Methods 0.000 abstract description 11
238000012270 DNA recombination Methods 0.000 abstract 1
210000004027 cell Anatomy 0.000 description 51
150000001413 amino acids Chemical class 0.000 description 48
108020004414 DNA Proteins 0.000 description 41
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 39
239000002299 complementary DNA Substances 0.000 description 33
102000004169 proteins and genes Human genes 0.000 description 28
229940024606 amino acid Drugs 0.000 description 27
235000001014 amino acid Nutrition 0.000 description 27
238000005516 engineering process Methods 0.000 description 27
235000018102 proteins Nutrition 0.000 description 26
210000001519 tissue Anatomy 0.000 description 23
239000000047 product Substances 0.000 description 20
108091028043 Nucleic acid sequence Proteins 0.000 description 19
108091032973 (ribonucleotides)n+m Proteins 0.000 description 17
230000008859 change Effects 0.000 description 17
208000032170 Congenital Abnormalities Diseases 0.000 description 14
108091034117 Oligonucleotide Proteins 0.000 description 14
230000006870 function Effects 0.000 description 13
238000003752 polymerase chain reaction Methods 0.000 description 13
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 12
206010028980 Neoplasm Diseases 0.000 description 11
108020004999 messenger RNA Proteins 0.000 description 11
239000000203 mixture Substances 0.000 description 11
238000001556 precipitation Methods 0.000 description 11
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
235000013372 meat Nutrition 0.000 description 10
241000894006 Bacteria Species 0.000 description 9
230000008034 disappearance Effects 0.000 description 9
230000000505 pernicious effect Effects 0.000 description 9
238000000926 separation method Methods 0.000 description 9
238000012360 testing method Methods 0.000 description 9
210000003414 extremity Anatomy 0.000 description 8
210000003205 muscle Anatomy 0.000 description 8
108091026890 Coding region Proteins 0.000 description 7
230000008827 biological function Effects 0.000 description 7
238000002474 experimental method Methods 0.000 description 7
238000012216 screening Methods 0.000 description 7
239000000243 solution Substances 0.000 description 7
238000005406 washing Methods 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
125000000539 amino acid group Chemical group 0.000 description 6
230000004071 biological effect Effects 0.000 description 6
210000000988 bone and bone Anatomy 0.000 description 6
230000002759 chromosomal effect Effects 0.000 description 6
210000000936 intestine Anatomy 0.000 description 6
239000000463 material Substances 0.000 description 6
239000012528 membrane Substances 0.000 description 6
210000005036 nerve Anatomy 0.000 description 6
230000008521 reorganization Effects 0.000 description 6
206010033799 Paralysis Diseases 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
208000035475 disorder Diseases 0.000 description 5
210000004962 mammalian cell Anatomy 0.000 description 5
239000003550 marker Substances 0.000 description 5
238000010369 molecular cloning Methods 0.000 description 5
210000001672 ovary Anatomy 0.000 description 5
108091092562 ribozyme Proteins 0.000 description 5
108090000994 Catalytic RNA Proteins 0.000 description 4
102000053642 Catalytic RNA Human genes 0.000 description 4
206010010356 Congenital anomaly Diseases 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
238000000636 Northern blotting Methods 0.000 description 4
241000283973 Oryctolagus cuniculus Species 0.000 description 4
230000002159 abnormal effect Effects 0.000 description 4
239000002671 adjuvant Substances 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
210000004556 brain Anatomy 0.000 description 4
150000001720 carbohydrates Chemical class 0.000 description 4
210000004292 cytoskeleton Anatomy 0.000 description 4
238000001514 detection method Methods 0.000 description 4
230000004064 dysfunction Effects 0.000 description 4
230000008175 fetal development Effects 0.000 description 4
230000001900 immune effect Effects 0.000 description 4
238000007901 in situ hybridization Methods 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
238000003780 insertion Methods 0.000 description 4
230000037431 insertion Effects 0.000 description 4
PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 4
239000007788 liquid Substances 0.000 description 4
230000008569 process Effects 0.000 description 4
150000003839 salts Chemical class 0.000 description 4
239000000126 substance Substances 0.000 description 4
210000001550 testis Anatomy 0.000 description 4
206010061619 Deformity Diseases 0.000 description 3
238000002965 ELISA Methods 0.000 description 3
108700024394 Exon Proteins 0.000 description 3
206010016717 Fistula Diseases 0.000 description 3
VNCNWQPIQYAMAK-ACZMJKKPSA-N Glu-Ser-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O VNCNWQPIQYAMAK-ACZMJKKPSA-N 0.000 description 3
241000238631 Hexapoda Species 0.000 description 3
206010027336 Menstruation delayed Diseases 0.000 description 3
239000000020 Nitrocellulose Substances 0.000 description 3
108700026244 Open Reading Frames Proteins 0.000 description 3
108091034057 RNA (poly(A)) Proteins 0.000 description 3
108020005091 Replication Origin Proteins 0.000 description 3
240000004808 Saccharomyces cerevisiae Species 0.000 description 3
206010040026 Sensory disturbance Diseases 0.000 description 3
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
238000002105 Southern blotting Methods 0.000 description 3
239000002253 acid Substances 0.000 description 3
230000001580 bacterial effect Effects 0.000 description 3
230000027455 binding Effects 0.000 description 3
239000000872 buffer Substances 0.000 description 3
210000004899 c-terminal region Anatomy 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
210000000349 chromosome Anatomy 0.000 description 3
238000005520 cutting process Methods 0.000 description 3
238000013016 damping Methods 0.000 description 3
210000003527 eukaryotic cell Anatomy 0.000 description 3
230000003890 fistula Effects 0.000 description 3
239000012530 fluid Substances 0.000 description 3
238000001415 gene therapy Methods 0.000 description 3
230000002068 genetic effect Effects 0.000 description 3
108060003552 hemocyanin Proteins 0.000 description 3
210000003917 human chromosome Anatomy 0.000 description 3
210000004754 hybrid cell Anatomy 0.000 description 3
238000013507 mapping Methods 0.000 description 3
210000001370 mediastinum Anatomy 0.000 description 3
VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 3
238000002156 mixing Methods 0.000 description 3
208000015357 muscle tissue disease Diseases 0.000 description 3
229920001220 nitrocellulos Polymers 0.000 description 3
239000002953 phosphate buffered saline Substances 0.000 description 3
238000000746 purification Methods 0.000 description 3
108091008146 restriction endonucleases Proteins 0.000 description 3
238000010839 reverse transcription Methods 0.000 description 3
238000003757 reverse transcription PCR Methods 0.000 description 3
239000001632 sodium acetate Substances 0.000 description 3
229960004249 sodium acetate Drugs 0.000 description 3
235000017281 sodium acetate Nutrition 0.000 description 3
210000002784 stomach Anatomy 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
230000017105 transposition Effects 0.000 description 3
241000701161 unidentified adenovirus Species 0.000 description 3
241001430294 unidentified retrovirus Species 0.000 description 3
210000004291 uterus Anatomy 0.000 description 3
210000001835 viscera Anatomy 0.000 description 3
230000006269 (delayed) early viral mRNA transcription Effects 0.000 description 2
102000007469 Actins Human genes 0.000 description 2
108010085238 Actins Proteins 0.000 description 2
208000003200 Adenoma Diseases 0.000 description 2
206010001233 Adenoma benign Diseases 0.000 description 2
206010002383 Angina Pectoris Diseases 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
206010009269 Cleft palate Diseases 0.000 description 2
108091033380 Coding strand Proteins 0.000 description 2
108020004705 Codon Proteins 0.000 description 2
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
108010067770 Endopeptidase K Proteins 0.000 description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
239000004471 Glycine Substances 0.000 description 2
108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
206010019468 Hemiplegia Diseases 0.000 description 2
101000589010 Homo sapiens Myomesin-1 Proteins 0.000 description 2
206010020772 Hypertension Diseases 0.000 description 2
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
101000589013 Mus musculus Myomesin-1 Proteins 0.000 description 2
102100032971 Myomesin-1 Human genes 0.000 description 2
206010028851 Necrosis Diseases 0.000 description 2
238000012408 PCR amplification Methods 0.000 description 2
102000002067 Protein Subunits Human genes 0.000 description 2
108010001267 Protein Subunits Proteins 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
108091081021 Sense strand Proteins 0.000 description 2
229920002684 Sepharose Polymers 0.000 description 2
238000012300 Sequence Analysis Methods 0.000 description 2
ADJDNJCSPNFFPI-FXQIFTODSA-N Ser-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CO ADJDNJCSPNFFPI-FXQIFTODSA-N 0.000 description 2
KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 2
239000000427 antigen Substances 0.000 description 2
230000000890 antigenic effect Effects 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
210000000709 aorta Anatomy 0.000 description 2
239000012472 biological sample Substances 0.000 description 2
238000001574 biopsy Methods 0.000 description 2
229940098773 bovine serum albumin Drugs 0.000 description 2
239000001110 calcium chloride Substances 0.000 description 2
229910001628 calcium chloride Inorganic materials 0.000 description 2
244000309466 calf Species 0.000 description 2
239000000969 carrier Substances 0.000 description 2
230000010261 cell growth Effects 0.000 description 2
230000004663 cell proliferation Effects 0.000 description 2
238000007385 chemical modification Methods 0.000 description 2
210000000038 chest Anatomy 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
230000014107 chromosome localization Effects 0.000 description 2
210000003792 cranial nerve Anatomy 0.000 description 2
230000007547 defect Effects 0.000 description 2
238000002405 diagnostic procedure Methods 0.000 description 2
238000001035 drying Methods 0.000 description 2
238000001962 electrophoresis Methods 0.000 description 2
238000004520 electroporation Methods 0.000 description 2
230000002708 enhancing effect Effects 0.000 description 2
238000000605 extraction Methods 0.000 description 2
238000006062 fragmentation reaction Methods 0.000 description 2
238000001502 gel electrophoresis Methods 0.000 description 2
108010055341 glutamyl-glutamic acid Proteins 0.000 description 2
239000005090 green fluorescent protein Substances 0.000 description 2
210000003128 head Anatomy 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
230000003053 immunization Effects 0.000 description 2
230000008595 infiltration Effects 0.000 description 2
238000001764 infiltration Methods 0.000 description 2
238000009413 insulation Methods 0.000 description 2
230000000968 intestinal effect Effects 0.000 description 2
229960000310 isoleucine Drugs 0.000 description 2
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
210000000867 larynx Anatomy 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
239000002502 liposome Substances 0.000 description 2
238000004811 liquid chromatography Methods 0.000 description 2
230000004807 localization Effects 0.000 description 2
230000033001 locomotion Effects 0.000 description 2
210000003141 lower extremity Anatomy 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
230000000998 lymphohematopoietic effect Effects 0.000 description 2
239000012139 lysis buffer Substances 0.000 description 2
201000001441 melanoma Diseases 0.000 description 2
230000027939 micturition Effects 0.000 description 2
230000002969 morbid Effects 0.000 description 2
230000035772 mutation Effects 0.000 description 2
230000017074 necrotic cell death Effects 0.000 description 2
238000012856 packing Methods 0.000 description 2
206010033675 panniculitis Diseases 0.000 description 2
208000003154 papilloma Diseases 0.000 description 2
230000001734 parasympathetic effect Effects 0.000 description 2
230000001575 pathological effect Effects 0.000 description 2
230000035790 physiological processes and functions Effects 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
239000004033 plastic Substances 0.000 description 2
229920002401 polyacrylamide Polymers 0.000 description 2
-1 polyoxyethylene Polymers 0.000 description 2
230000002265 prevention Effects 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
210000001236 prokaryotic cell Anatomy 0.000 description 2
230000002285 radioactive effect Effects 0.000 description 2
238000003259 recombinant expression Methods 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
210000002345 respiratory system Anatomy 0.000 description 2
238000004062 sedimentation Methods 0.000 description 2
238000012163 sequencing technique Methods 0.000 description 2
238000012882 sequential analysis Methods 0.000 description 2
210000003625 skull Anatomy 0.000 description 2
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
210000001032 spinal nerve Anatomy 0.000 description 2
230000002269 spontaneous effect Effects 0.000 description 2
230000002889 sympathetic effect Effects 0.000 description 2
208000011580 syndromic disease Diseases 0.000 description 2
238000013518 transcription Methods 0.000 description 2
230000035897 transcription Effects 0.000 description 2
238000010361 transduction Methods 0.000 description 2
230000026683 transduction Effects 0.000 description 2
230000009466 transformation Effects 0.000 description 2
210000000689 upper leg Anatomy 0.000 description 2
235000013311 vegetables Nutrition 0.000 description 2
208000029257 vision disease Diseases 0.000 description 2
230000004304 visual acuity Effects 0.000 description 2
238000001262 western blot Methods 0.000 description 2
JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 1
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 description 1
101150072531 10 gene Proteins 0.000 description 1
UZGKAASZIMOAMU-UHFFFAOYSA-N 124177-85-1 Chemical compound NP(=O)=O UZGKAASZIMOAMU-UHFFFAOYSA-N 0.000 description 1
SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 1
108010022579 ATP dependent 26S protease Proteins 0.000 description 1
241000540905 Acnemia Species 0.000 description 1
IORKCNUBHNIMKY-CIUDSAMLSA-N Ala-Pro-Glu Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O IORKCNUBHNIMKY-CIUDSAMLSA-N 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
206010002120 Anal atresia Diseases 0.000 description 1
206010056292 Androgen-Insensitivity Syndrome Diseases 0.000 description 1
208000000103 Anorexia Nervosa Diseases 0.000 description 1
108020005544 Antisense RNA Proteins 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
QXHVOUSPVAWEMX-ZLUOBGJFSA-N Asp-Asp-Ser Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O QXHVOUSPVAWEMX-ZLUOBGJFSA-N 0.000 description 1
NAAAPCLFJPURAM-HJGDQZAQSA-N Asp-Thr-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)O)N)O NAAAPCLFJPURAM-HJGDQZAQSA-N 0.000 description 1
206010003598 Atelectasis Diseases 0.000 description 1
206010003658 Atrial Fibrillation Diseases 0.000 description 1
241000972773 Aulopiformes Species 0.000 description 1
206010004272 Benign hydatidiform mole Diseases 0.000 description 1
206010004663 Biliary colic Diseases 0.000 description 1
208000002880 Bladder exstrophy Diseases 0.000 description 1
102000000584 Calmodulin Human genes 0.000 description 1
108010041952 Calmodulin Proteins 0.000 description 1
206010007556 Cardiac failure acute Diseases 0.000 description 1
206010007558 Cardiac failure chronic Diseases 0.000 description 1
206010007747 Cataract congenital Diseases 0.000 description 1
206010008190 Cerebrovascular accident Diseases 0.000 description 1
208000006332 Choriocarcinoma Diseases 0.000 description 1
208000000668 Chronic Pancreatitis Diseases 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
206010010317 Congenital absence of bile ducts Diseases 0.000 description 1
208000026372 Congenital cystic kidney disease Diseases 0.000 description 1
206010018325 Congenital glaucomas Diseases 0.000 description 1
206010068321 Congenital inguinal hernia Diseases 0.000 description 1
206010010539 Congenital megacolon Diseases 0.000 description 1
206010010774 Constipation Diseases 0.000 description 1
206010011498 Cryptorchism Diseases 0.000 description 1
206010011732 Cyst Diseases 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
230000004544 DNA amplification Effects 0.000 description 1
238000000018 DNA microarray Methods 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
206010011878 Deafness Diseases 0.000 description 1
206010011882 Deafness congenital Diseases 0.000 description 1
206010012118 Defect conduction intraventricular Diseases 0.000 description 1
208000019505 Deglutition disease Diseases 0.000 description 1
241000702421 Dependoparvovirus Species 0.000 description 1
206010012565 Developmental glaucoma Diseases 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
108010053187 Diphtheria Toxin Proteins 0.000 description 1
102000016607 Diphtheria Toxin Human genes 0.000 description 1
208000003164 Diplopia Diseases 0.000 description 1
208000027877 Disorders of Sex Development Diseases 0.000 description 1
206010013554 Diverticulum Diseases 0.000 description 1
206010013613 Double ureter Diseases 0.000 description 1
208000007033 Dysgerminoma Diseases 0.000 description 1
208000012661 Dyskinesia Diseases 0.000 description 1
206010013935 Dysmenorrhoea Diseases 0.000 description 1
201000009051 Embryonal Carcinoma Diseases 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
108010042407 Endonucleases Proteins 0.000 description 1
102000004533 Endonucleases Human genes 0.000 description 1
241000305071 Enterobacterales Species 0.000 description 1
208000008967 Enuresis Diseases 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
241000206602 Eukaryota Species 0.000 description 1
208000004929 Facial Paralysis Diseases 0.000 description 1
206010053717 Fibrous histiocytoma Diseases 0.000 description 1
229920001917 Ficoll Polymers 0.000 description 1
206010061159 Foot deformity Diseases 0.000 description 1
208000032974 Gagging Diseases 0.000 description 1
206010017577 Gait disturbance Diseases 0.000 description 1
208000007882 Gastritis Diseases 0.000 description 1
108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
208000007569 Giant Cell Tumors Diseases 0.000 description 1
208000010412 Glaucoma Diseases 0.000 description 1
208000032612 Glial tumor Diseases 0.000 description 1
206010018338 Glioma Diseases 0.000 description 1
208000018779 Globus Sensation Diseases 0.000 description 1
PJBVXVBTTFZPHJ-GUBZILKMSA-N Glu-Leu-Asp Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CCC(=O)O)N PJBVXVBTTFZPHJ-GUBZILKMSA-N 0.000 description 1
IRXNJYPKBVERCW-DCAQKATOSA-N Glu-Leu-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O IRXNJYPKBVERCW-DCAQKATOSA-N 0.000 description 1
CQAHWYDHKUWYIX-YUMQZZPRSA-N Glu-Pro-Gly Chemical compound OC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O CQAHWYDHKUWYIX-YUMQZZPRSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
QSTLUOIOYLYLLF-WDSKDSINSA-N Gly-Asp-Glu Chemical compound [H]NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O QSTLUOIOYLYLLF-WDSKDSINSA-N 0.000 description 1
NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 1
108020005004 Guide RNA Proteins 0.000 description 1
208000006358 Hand Deformities Diseases 0.000 description 1
208000004592 Hirschsprung disease Diseases 0.000 description 1
101000829958 Homo sapiens N-acetyllactosaminide beta-1,6-N-acetylglucosaminyl-transferase Proteins 0.000 description 1
208000000203 Hyaline Membrane Disease Diseases 0.000 description 1
208000006937 Hydatidiform mole Diseases 0.000 description 1
208000031226 Hyperlipidaemia Diseases 0.000 description 1
208000013016 Hypoglycemia Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
208000032571 Infant acute respiratory distress syndrome Diseases 0.000 description 1
208000035478 Interatrial communication Diseases 0.000 description 1
108091092195 Intron Proteins 0.000 description 1
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
NEEOBPIXKWSBRF-IUCAKERBSA-N Leu-Glu-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O NEEOBPIXKWSBRF-IUCAKERBSA-N 0.000 description 1
ICYRCNICGBJLGM-HJGDQZAQSA-N Leu-Thr-Asp Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC(O)=O ICYRCNICGBJLGM-HJGDQZAQSA-N 0.000 description 1
102000003960 Ligases Human genes 0.000 description 1
108090000364 Ligases Proteins 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
GJJQCBVRWDGLMQ-GUBZILKMSA-N Lys-Glu-Ala Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O GJJQCBVRWDGLMQ-GUBZILKMSA-N 0.000 description 1
WGLAORUKDGRINI-WDCWCFNPSA-N Lys-Glu-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O WGLAORUKDGRINI-WDCWCFNPSA-N 0.000 description 1
UQRZFMQQXXJTTF-AVGNSLFASA-N Lys-Lys-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O UQRZFMQQXXJTTF-AVGNSLFASA-N 0.000 description 1
HVAUKHLDSDDROB-KKUMJFAQSA-N Lys-Lys-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O HVAUKHLDSDDROB-KKUMJFAQSA-N 0.000 description 1
208000000172 Medulloblastoma Diseases 0.000 description 1
206010027406 Mesothelioma Diseases 0.000 description 1
DSZFTPCSFVWMKP-DCAQKATOSA-N Met-Ser-Lys Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCCN DSZFTPCSFVWMKP-DCAQKATOSA-N 0.000 description 1
208000009795 Microphthalmos Diseases 0.000 description 1
206010027926 Monoplegia Diseases 0.000 description 1
208000034578 Multiple myelomas Diseases 0.000 description 1
208000001089 Multiple system atrophy Diseases 0.000 description 1
206010028372 Muscular weakness Diseases 0.000 description 1
102000015695 Myristoylated Alanine-Rich C Kinase Substrate Human genes 0.000 description 1
108010063737 Myristoylated Alanine-Rich C Kinase Substrate Proteins 0.000 description 1
CZCIKBSVHDNIDH-NSHDSACASA-N N(alpha)-methyl-L-tryptophan Chemical compound C1=CC=C2C(C[C@H]([NH2+]C)C([O-])=O)=CNC2=C1 CZCIKBSVHDNIDH-NSHDSACASA-N 0.000 description 1
SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 1
XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 1
102100023315 N-acetyllactosaminide beta-1,6-N-acetylglucosaminyl-transferase Human genes 0.000 description 1
108010002311 N-glycylglutamic acid Proteins 0.000 description 1
125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
CZCIKBSVHDNIDH-UHFFFAOYSA-N Nalpha-methyl-DL-tryptophan Natural products C1=CC=C2C(CC(NC)C(O)=O)=CNC2=C1 CZCIKBSVHDNIDH-UHFFFAOYSA-N 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
206010028974 Neonatal respiratory distress syndrome Diseases 0.000 description 1
206010029260 Neuroblastoma Diseases 0.000 description 1
208000008846 Neurocytoma Diseases 0.000 description 1
208000008589 Obesity Diseases 0.000 description 1
206010061876 Obstruction Diseases 0.000 description 1
108010038807 Oligopeptides Proteins 0.000 description 1
102000015636 Oligopeptides Human genes 0.000 description 1
206010031127 Orthostatic hypotension Diseases 0.000 description 1
208000008701 Ovotesticular Disorders of Sex Development Diseases 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
206010033645 Pancreatitis Diseases 0.000 description 1
206010033647 Pancreatitis acute Diseases 0.000 description 1
206010033649 Pancreatitis chronic Diseases 0.000 description 1
206010033892 Paraplegia Diseases 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
206010070872 Persistent pupillary membrane Diseases 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
XQLBWXHVZVBNJM-FXQIFTODSA-N Pro-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 XQLBWXHVZVBNJM-FXQIFTODSA-N 0.000 description 1
GFHXZNVJIKMAGO-IHRRRGAJSA-N Pro-Phe-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(O)=O GFHXZNVJIKMAGO-IHRRRGAJSA-N 0.000 description 1
229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
102000003923 Protein Kinase C Human genes 0.000 description 1
108090000315 Protein Kinase C Proteins 0.000 description 1
241000125945 Protoparvovirus Species 0.000 description 1
201000005613 Pseudohermaphroditism Diseases 0.000 description 1
208000007123 Pulmonary Atelectasis Diseases 0.000 description 1
206010037423 Pulmonary oedema Diseases 0.000 description 1
208000003782 Raynaud disease Diseases 0.000 description 1
208000012322 Raynaud phenomenon Diseases 0.000 description 1
208000001647 Renal Insufficiency Diseases 0.000 description 1
206010038419 Renal colic Diseases 0.000 description 1
206010038481 Renal necrosis Diseases 0.000 description 1
208000004756 Respiratory Insufficiency Diseases 0.000 description 1
108010039491 Ricin Proteins 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
BFDMCHRDSYTOLE-UHFFFAOYSA-N SC#N.NC(N)=N.ClC(Cl)Cl.OC1=CC=CC=C1 Chemical compound SC#N.NC(N)=N.ClC(Cl)Cl.OC1=CC=CC=C1 BFDMCHRDSYTOLE-UHFFFAOYSA-N 0.000 description 1
241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
FPCGZYMRFFIYIH-CIUDSAMLSA-N Ser-Lys-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O FPCGZYMRFFIYIH-CIUDSAMLSA-N 0.000 description 1
FKYWFUYPVKLJLP-DCAQKATOSA-N Ser-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CO FKYWFUYPVKLJLP-DCAQKATOSA-N 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
206010040639 Sick sinus syndrome Diseases 0.000 description 1
206010040738 Sinus arrest Diseases 0.000 description 1
208000033041 Somatoform disorder gastrointestinal Diseases 0.000 description 1
102000005890 Spectrin Human genes 0.000 description 1
108010019965 Spectrin Proteins 0.000 description 1
241000187747 Streptomyces Species 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
208000003734 Supraventricular Tachycardia Diseases 0.000 description 1
206010043101 Talipes Diseases 0.000 description 1
206010043276 Teratoma Diseases 0.000 description 1
108700007696 Tetrahydrofolate Dehydrogenase Proteins 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
102000006601 Thymidine Kinase Human genes 0.000 description 1
108020004440 Thymidine kinase Proteins 0.000 description 1
206010051320 Thyroglossal cyst Diseases 0.000 description 1
208000009205 Tinnitus Diseases 0.000 description 1
206010044310 Tracheo-oesophageal fistula Diseases 0.000 description 1
208000005864 Tracheoesophageal Fistula Diseases 0.000 description 1
108700029229 Transcriptional Regulatory Elements Proteins 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
239000006035 Tryptophane Substances 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
206010046542 Urinary hesitation Diseases 0.000 description 1
208000036826 VIIth nerve paralysis Diseases 0.000 description 1
206010046879 Vaginal atresia Diseases 0.000 description 1
BRPKEERLGYNCNC-NHCYSSNCSA-N Val-Glu-Arg Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N BRPKEERLGYNCNC-NHCYSSNCSA-N 0.000 description 1
LGXUZJIQCGXKGZ-QXEWZRGKSA-N Val-Pro-Asn Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(=O)N)C(=O)O)N LGXUZJIQCGXKGZ-QXEWZRGKSA-N 0.000 description 1
GBIUHAYJGWVNLN-AEJSXWLSSA-N Val-Ser-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N1CCC[C@@H]1C(=O)O)N GBIUHAYJGWVNLN-AEJSXWLSSA-N 0.000 description 1
GBIUHAYJGWVNLN-UHFFFAOYSA-N Val-Ser-Pro Natural products CC(C)C(N)C(=O)NC(CO)C(=O)N1CCCC1C(O)=O GBIUHAYJGWVNLN-UHFFFAOYSA-N 0.000 description 1
208000001910 Ventricular Heart Septal Defects Diseases 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
206010047709 Vomiting psychogenic Diseases 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
210000003208 abducens nerve Anatomy 0.000 description 1
210000002187 accessory nerve Anatomy 0.000 description 1
230000009471 action Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000012190 activator Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
201000003229 acute pancreatitis Diseases 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
210000004100 adrenal gland Anatomy 0.000 description 1
210000001943 adrenal medulla Anatomy 0.000 description 1
238000005377 adsorption chromatography Methods 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
108010005233 alanylglutamic acid Proteins 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
239000005030 aluminium foil Substances 0.000 description 1
210000001909 alveolar process Anatomy 0.000 description 1
238000003277 amino acid sequence analysis Methods 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
206010002320 anencephaly Diseases 0.000 description 1
210000003423 ankle Anatomy 0.000 description 1
208000010133 annular pancreas Diseases 0.000 description 1
230000002788 anti-peptide Effects 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
108010062796 arginyllysine Proteins 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
108010077245 asparaginyl-proline Proteins 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
108010047857 aspartylglycine Proteins 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
208000013914 atrial heart septal defect Diseases 0.000 description 1
206010003664 atrial septal defect Diseases 0.000 description 1
238000002869 basic local alignment search tool Methods 0.000 description 1
230000008901 benefit Effects 0.000 description 1
208000001119 benign fibrous histiocytoma Diseases 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
201000005271 biliary atresia Diseases 0.000 description 1
230000000975 bioactive effect Effects 0.000 description 1
238000011953 bioanalysis Methods 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
210000004958 brain cell Anatomy 0.000 description 1
210000005013 brain tissue Anatomy 0.000 description 1
UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000002775 capsule Substances 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
210000000748 cardiovascular system Anatomy 0.000 description 1
210000000845 cartilage Anatomy 0.000 description 1
210000001638 cerebellum Anatomy 0.000 description 1
208000026106 cerebrovascular disease Diseases 0.000 description 1
239000012295 chemical reaction liquid Substances 0.000 description 1
208000003167 cholangitis Diseases 0.000 description 1
208000023652 chronic gastritis Diseases 0.000 description 1
230000004087 circulation Effects 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
206010009259 cleft lip Diseases 0.000 description 1
238000000975 co-precipitation Methods 0.000 description 1
210000000860 cochlear nerve Anatomy 0.000 description 1
239000003184 complementary RNA Substances 0.000 description 1
230000001143 conditioned effect Effects 0.000 description 1
108091036078 conserved sequence Proteins 0.000 description 1
238000010276 construction Methods 0.000 description 1
208000012839 conversion disease Diseases 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
201000000160 cryptorchidism Diseases 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
208000031513 cyst Diseases 0.000 description 1
SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
231100000895 deafness Toxicity 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
238000010586 diagram Methods 0.000 description 1
230000029087 digestion Effects 0.000 description 1
102000004419 dihydrofolate reductase Human genes 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
238000009826 distribution Methods 0.000 description 1
208000002173 dizziness Diseases 0.000 description 1
229940079593 drug Drugs 0.000 description 1
201000006549 dyspepsia Diseases 0.000 description 1
235000013399 edible fruits Nutrition 0.000 description 1
210000002310 elbow joint Anatomy 0.000 description 1
210000000750 endocrine system Anatomy 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
201000011384 erythromelalgia Diseases 0.000 description 1
230000005284 excitation Effects 0.000 description 1
238000010195 expression analysis Methods 0.000 description 1
230000001815 facial effect Effects 0.000 description 1
210000000256 facial nerve Anatomy 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
210000003754 fetus Anatomy 0.000 description 1
239000000835 fiber Substances 0.000 description 1
230000004992 fission Effects 0.000 description 1
206010016766 flatulence Diseases 0.000 description 1
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
210000000245 forearm Anatomy 0.000 description 1
238000013467 fragmentation Methods 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
201000008361 ganglioneuroma Diseases 0.000 description 1
239000007789 gas Substances 0.000 description 1
208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
201000007116 gestational trophoblastic neoplasm Diseases 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
210000001932 glossopharyngeal nerve Anatomy 0.000 description 1
239000008103 glucose Substances 0.000 description 1
229960002989 glutamic acid Drugs 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
230000036449 good health Effects 0.000 description 1
230000012010 growth Effects 0.000 description 1
ZRALSGWEFCBTJO-UHFFFAOYSA-O guanidinium Chemical compound NC(N)=[NH2+] ZRALSGWEFCBTJO-UHFFFAOYSA-O 0.000 description 1
ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
208000016354 hearing loss disease Diseases 0.000 description 1
230000007866 hepatic necrosis Effects 0.000 description 1
206010019692 hepatic necrosis Diseases 0.000 description 1
239000000833 heterodimer Substances 0.000 description 1
235000014304 histidine Nutrition 0.000 description 1
125000000487 histidyl group Chemical class [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
210000002758 humerus Anatomy 0.000 description 1
210000004408 hybridoma Anatomy 0.000 description 1
208000003906 hydrocephalus Diseases 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
208000020346 hyperlipoproteinemia Diseases 0.000 description 1
230000001631 hypertensive effect Effects 0.000 description 1
210000001169 hypoglossal nerve Anatomy 0.000 description 1
230000002218 hypoglycaemic effect Effects 0.000 description 1
206010021093 hypospadias Diseases 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000036039 immunity Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
238000003364 immunohistochemistry Methods 0.000 description 1
238000001114 immunoprecipitation Methods 0.000 description 1
230000002637 immunotoxin Effects 0.000 description 1
239000002596 immunotoxin Substances 0.000 description 1
231100000608 immunotoxin Toxicity 0.000 description 1
229940051026 immunotoxin Drugs 0.000 description 1
208000002358 imperforate anus Diseases 0.000 description 1
230000008676 import Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
230000001788 irregular Effects 0.000 description 1
230000000622 irritating effect Effects 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
208000016274 isolated tracheo-esophageal fistula Diseases 0.000 description 1
238000002955 isolation Methods 0.000 description 1
BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
230000000155 isotopic effect Effects 0.000 description 1
206010023332 keratitis Diseases 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
210000003127 knee Anatomy 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
YDTFRJLNMPSCFM-YDALLXLXSA-M levothyroxine sodium anhydrous Chemical compound [Na+].IC1=CC(C[C@H](N)C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 YDTFRJLNMPSCFM-YDALLXLXSA-M 0.000 description 1
210000005228 liver tissue Anatomy 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
210000001365 lymphatic vessel Anatomy 0.000 description 1
108010003700 lysyl aspartic acid Proteins 0.000 description 1
108010064235 lysylglycine Proteins 0.000 description 1
238000010841 mRNA extraction Methods 0.000 description 1
230000036244 malformation Effects 0.000 description 1
210000005075 mammary gland Anatomy 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
230000018984 mastication Effects 0.000 description 1
238000010077 mastication Methods 0.000 description 1
230000013011 mating Effects 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
238000010297 mechanical methods and process Methods 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
210000002418 meninge Anatomy 0.000 description 1
206010027191 meningioma Diseases 0.000 description 1
210000000713 mesentery Anatomy 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000031864 metaphase Effects 0.000 description 1
WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
238000000520 microinjection Methods 0.000 description 1
201000010478 microphthalmia Diseases 0.000 description 1
230000000394 mitotic effect Effects 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
210000002161 motor neuron Anatomy 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
230000003387 muscular Effects 0.000 description 1
230000036473 myasthenia Effects 0.000 description 1
206010028417 myasthenia gravis Diseases 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
210000001989 nasopharynx Anatomy 0.000 description 1
239000005445 natural material Substances 0.000 description 1
210000003739 neck Anatomy 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
210000004126 nerve fiber Anatomy 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
201000010193 neural tube defect Diseases 0.000 description 1
208000007538 neurilemmoma Diseases 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
201000002652 newborn respiratory distress syndrome Diseases 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
238000007899 nucleic acid hybridization Methods 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
206010029864 nystagmus Diseases 0.000 description 1
235000020824 obesity Nutrition 0.000 description 1
210000002589 oculomotor nerve Anatomy 0.000 description 1
206010030875 ophthalmoplegia Diseases 0.000 description 1
210000001328 optic nerve Anatomy 0.000 description 1
230000008520 organization Effects 0.000 description 1
210000002220 organoid Anatomy 0.000 description 1
201000010302 ovarian serous cystadenocarcinoma Diseases 0.000 description 1
230000036407 pain Effects 0.000 description 1
208000035824 paresthesia Diseases 0.000 description 1
208000003278 patent ductus arteriosus Diseases 0.000 description 1
208000000689 peptic esophagitis Diseases 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
230000008447 perception Effects 0.000 description 1
208000029308 periodic paralysis Diseases 0.000 description 1
210000005259 peripheral blood Anatomy 0.000 description 1
239000011886 peripheral blood Substances 0.000 description 1
210000001428 peripheral nervous system Anatomy 0.000 description 1
239000012071 phase Substances 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
208000028591 pheochromocytoma Diseases 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
239000003123 plant toxin Substances 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
208000030761 polycystic kidney disease Diseases 0.000 description 1
229920002981 polyvinylidene fluoride Polymers 0.000 description 1
230000037452 priming Effects 0.000 description 1
KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
238000001742 protein purification Methods 0.000 description 1
210000001147 pulmonary artery Anatomy 0.000 description 1
208000005333 pulmonary edema Diseases 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
208000009138 pulmonary valve stenosis Diseases 0.000 description 1
208000030390 pulmonic stenosis Diseases 0.000 description 1
235000019633 pungent taste Nutrition 0.000 description 1
210000001747 pupil Anatomy 0.000 description 1
238000000197 pyrolysis Methods 0.000 description 1
238000012797 qualification Methods 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
238000003156 radioimmunoprecipitation Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000029865 regulation of blood pressure Effects 0.000 description 1
238000004153 renaturation Methods 0.000 description 1
210000004994 reproductive system Anatomy 0.000 description 1
201000004193 respiratory failure Diseases 0.000 description 1
210000003019 respiratory muscle Anatomy 0.000 description 1
230000004044 response Effects 0.000 description 1
210000001995 reticulocyte Anatomy 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
239000002342 ribonucleoside Substances 0.000 description 1
230000000630 rising effect Effects 0.000 description 1
210000000954 sacrococcygeal region Anatomy 0.000 description 1
235000019515 salmon Nutrition 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
206010039667 schwannoma Diseases 0.000 description 1
230000007017 scission Effects 0.000 description 1
238000007789 sealing Methods 0.000 description 1
230000028327 secretion Effects 0.000 description 1
230000008786 sensory perception of smell Effects 0.000 description 1
208000005893 serous cystadenoma Diseases 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
108010026333 seryl-proline Proteins 0.000 description 1
230000035939 shock Effects 0.000 description 1
210000000323 shoulder joint Anatomy 0.000 description 1
230000007781 signaling event Effects 0.000 description 1
210000002027 skeletal muscle Anatomy 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
210000001082 somatic cell Anatomy 0.000 description 1
241000894007 species Species 0.000 description 1
238000010183 spectrum analysis Methods 0.000 description 1
210000000278 spinal cord Anatomy 0.000 description 1
206010041823 squamous cell carcinoma Diseases 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
210000002504 synaptic vesicle Anatomy 0.000 description 1
210000001258 synovial membrane Anatomy 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
229920001059 synthetic polymer Polymers 0.000 description 1
229910052714 tellurium Inorganic materials 0.000 description 1
PORWMNRCUJJQNO-UHFFFAOYSA-N tellurium atom Chemical compound [Te] PORWMNRCUJJQNO-UHFFFAOYSA-N 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
210000001541 thymus gland Anatomy 0.000 description 1
231100000886 tinnitus Toxicity 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
238000001890 transfection Methods 0.000 description 1
238000003151 transfection method Methods 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
230000007704 transition Effects 0.000 description 1
230000014621 translational initiation Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
210000003901 trigeminal nerve Anatomy 0.000 description 1
HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
229940038773 trisodium citrate Drugs 0.000 description 1
210000003076 trochlear nerve Anatomy 0.000 description 1
208000013327 true hermaphroditism Diseases 0.000 description 1
229960004799 tryptophan Drugs 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
230000036269 ulceration Effects 0.000 description 1
238000002525 ultrasonication Methods 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1
210000001364 upper extremity Anatomy 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
210000001635 urinary tract Anatomy 0.000 description 1
210000003741 urothelium Anatomy 0.000 description 1
238000001291 vacuum drying Methods 0.000 description 1
210000001186 vagus nerve Anatomy 0.000 description 1
201000003130 ventricular septal defect Diseases 0.000 description 1
239000013603 viral vector Substances 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
230000000007 visual effect Effects 0.000 description 1
230000008673 vomiting Effects 0.000 description 1
210000000707 wrist Anatomy 0.000 description 1
210000005253 yeast cell Anatomy 0.000 description 1

Images

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Toxicology (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Peptides Or Proteins (AREA)

CN 00116591 2000-06-19 2000-06-19 一种新的多肽——人内收蛋白beta亚基10和编码这种多肽的多核苷酸 Pending CN1329055A (zh)

Priority Applications (3)

Application Number	Priority Date	Filing Date	Title
CN 00116591 CN1329055A (zh)	2000-06-19	2000-06-19	一种新的多肽——人内收蛋白beta亚基10和编码这种多肽的多核苷酸
AU93624/01A AU9362401A (en)	2000-06-19	2001-06-18	A novel polypeptide - human beta adducin 10 and a polynucleotide encoding the same
PCT/CN2001/000989 WO2002002617A1 (fr)	2000-06-19	2001-06-18	Nouveau polypeptide, sous-unite beta 10 d'adductine humaine, et polynucleotide codant ce polypeptide

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CN 00116591 CN1329055A (zh)	2000-06-19	2000-06-19	一种新的多肽——人内收蛋白beta亚基10和编码这种多肽的多核苷酸

Publications (1)

Publication Number	Publication Date
CN1329055A true CN1329055A (zh)	2002-01-02

Family

ID=4585995

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CN 00116591 Pending CN1329055A (zh)	2000-06-19	2000-06-19	一种新的多肽——人内收蛋白beta亚基10和编码这种多肽的多核苷酸

Country Status (3)

Country	Link
CN (1)	CN1329055A (fr)
AU (1)	AU9362401A (fr)
WO (1)	WO2002002617A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN112679596A (zh) *	2021-01-15	2021-04-20	武汉大学	一种内收蛋白的抗原肽及其抗体与应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20210346662A1 (en)	2018-10-23	2021-11-11	Kindeva Drug Delivery L.P.	Tamper evident transdermal patch

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH09271384A (ja) *	1996-04-01	1997-10-21	Otsuka Pharmaceut Co Ltd	ヒト遺伝子

2000
- 2000-06-19 CN CN 00116591 patent/CN1329055A/zh active Pending
2001
- 2001-06-18 AU AU93624/01A patent/AU9362401A/en not_active Abandoned
- 2001-06-18 WO PCT/CN2001/000989 patent/WO2002002617A1/fr not_active Ceased

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN112679596A (zh) *	2021-01-15	2021-04-20	武汉大学	一种内收蛋白的抗原肽及其抗体与应用
CN112679596B (zh) *	2021-01-15	2022-03-15	武汉大学	一种内收蛋白的抗原肽及其抗体与应用

Also Published As

Publication number	Publication date
AU9362401A (en)	2002-01-14
WO2002002617A1 (fr)	2002-01-10

Publication	Publication Date	Title
CN1329055A (zh)	2002-01-02	一种新的多肽——人内收蛋白beta亚基10和编码这种多肽的多核苷酸
CN1381476A (zh)	2002-11-27	一种多肽——人肿瘤内皮标记－30.69和编码这种多肽的多核苷酸
CN1328038A (zh)	2001-12-26	一种新的多肽——人肌动蛋白相关蛋白13e－32和编码这种多肽的多核苷酸
CN1339492A (zh)	2002-03-13	一种新的多肽——人翻译起始因子亚单位eIF4E结合蛋白17.27和编码这种多肽的多核苷酸
CN1331104A (zh)	2002-01-16	一种新的多肽——skm－Bop蛋白39和编码这种多肽的多核苷酸
CN1339480A (zh)	2002-03-13	一种新的多肽——人c2h2型锌指蛋白11.99和编码这种多肽的多核苷酸
CN1339453A (zh)	2002-03-13	一种新的多肽——双线rna结合锌指蛋白25.19和编码这种多肽的多核苷酸
CN1341621A (zh)	2002-03-27	一种新的多肽——人U2 snRNP辅助因子小亚基26－24.86和编码这种多肽的多核苷酸
CN1339478A (zh)	2002-03-13	一种新的多肽——人l1因子orf2相关蛋白10.78和编码这种多肽的多核苷酸
CN1376686A (zh)	2002-10-30	一种多肽——缺刻蛋白－34.32和编码这种多肽的多核苷酸
CN1339501A (zh)	2002-03-13	一种新的多肽——人肌动蛋白相似蛋白56.43和编码这种多肽的多核苷酸
CN1363608A (zh)	2002-08-14	一种新的多肽——核糖体蛋白 s19－35.53 和编码这种多肽的多核苷酸
CN1382723A (zh)	2002-12-04	一种多肽——钙调结合蛋白－44.44和编码这种多肽的多核苷酸
CN1341630A (zh)	2002-03-27	一种新的多肽——人胰岛细胞抗原p69(ICAp69)28－9.13和编码这种多肽的多核苷酸
CN1341642A (zh)	2002-03-27	一种新的多肽——人Hsmarl蛋白15.95和编码这种多肽的多核苷酸
CN1382704A (zh)	2002-12-04	一种多肽——β－人微管蛋白－11.44和编码这种多肽的多核苷酸
CN1345797A (zh)	2002-04-24	一种新的多肽——人锌指(zn 84)蛋白81－68.09和编码这种多肽的多核苷酸
CN1380326A (zh)	2002-11-20	一种多肽——性别决定蛋白－85.69和编码这种多肽的多核苷酸
CN1341656A (zh)	2002-03-27	一种新的多肽——人锌指蛋白135－29.81和编码这种多肽的多核苷酸
CN1376680A (zh)	2002-10-30	一种多肽——人融合蛋白－19.8和编码这种多肽的多核苷酸
CN1339489A (zh)	2002-03-13	一种新的多肽——人视黄酸效应蛋白53.57和编码这种多肽的多核苷酸
CN1382717A (zh)	2002-12-04	一种多肽——基因修复功能相关蛋白－34.1和编码这种多肽的多核苷酸
CN1338469A (zh)	2002-03-06	一种新的多肽——人l1因子orf2相关蛋白10.45和编码这种多肽的多核苷酸
CN1339598A (zh)	2002-03-13	一种新的多肽——人atp依赖的rna螺旋酶20.24和编码这种多肽的多核苷酸
CN1341624A (zh)	2002-03-27	一种新的多肽——人多配体蛋白聚糖4相关蛋白16.39和编码这种多肽的多核苷酸

Legal Events

Date	Code	Title
2002-01-02	C06	Publication
2002-01-02	PB01	Publication
2004-03-03	C02	Deemed withdrawal of patent application after publication (patent law 2001)
2004-03-03	WD01	Invention patent application deemed withdrawn after publication